Gilead posted strong HIV-led growth, with base business sales up 16% and management raising full-year guidance. The stock still looks fairly valued near consensus, keeping the call at Hold.
Gilead Sciences (GILD) is a high-quality HIV franchise financing a broader move into oncology, cell therapy, and inflammation. The investment case rests on three facts: third-quarter 2026 base business sales rose 16.0% year over year to $8.2B, HIV sales rose 18.0% to $6.2B, and management raised full-year 2026 base business revenue guidance by $1.6B from its initial outlook.
The business has real operating momentum. Biktarvy generated $4.1B in third-quarter sales, Trodelvy grew 42.0% to $506M, and Livdelzi rose 93.0% to $203M. Yeztugo also reached $305M in quarterly sales and is tracking toward approximately $1.0B in full-year sales. This is a stronger growth mix than Gilead had several years ago, when the company relied more heavily on mature HIV products and hepatitis C revenue.
The stock is less compelling as a bargain. At $170.68, GILD trades at 17.3x forward earnings, carries a PEG ratio of 2.5x, and offers a 5.0% free-cash-flow yield. The analyst target of $170.88 is close to the current quote, while 2026 earnings guidance includes a loss caused by $12.4B of acquired in-process research and development charges.
The balanced conclusion is Hold. Gilead's HIV leadership, cash generation, and launch pipeline support a durable medium-term story, but policy pressure on Biktarvy, competitive cell therapy results, acquisition charges, and a valuation near consensus limit the margin of safety.
Gilead Sciences is a U.S.-based biopharmaceutical company headquartered in Foster City, California. Founded in 1987 and listed on Nasdaq under GILD, the company employs approximately 17,000 people and sells products through commercial operations in the United States, Europe, and other international markets.
HIV remains the economic center of the company. In 2025, Biktarvy produced $14.3B of revenue, equal to 48.7% of total reported revenue in the segment data. Descovy generated $2.8B, while Genvoya and Odefsey generated $1.5B and $1.2B, respectively. This concentration creates a powerful cash engine, but it also makes payer decisions and HIV competition especially important.
Gilead's newer strategy is to use that cash engine to fund a wider product base. Trodelvy, Livdelzi, Yeztugo, anito-cel, and the inflammation pipeline are intended to reduce dependence on a single franchise. The strategy is sensible, although oncology and cell therapy carry more clinical and commercial uncertainty than established HIV treatment.
HIV is the strongest segment. Third-quarter sales reached $6.2B, up 18.0% year over year, with growth from treatment, prevention, pricing, and inventory. Biktarvy sales rose 10.0% to $4.1B, while Descovy sales reached $1.0B, up 49.0%. Yeztugo added $305M and gave the prevention portfolio a fast-growing long-acting product.
Liver disease is becoming a more useful contributor. Third-quarter liver disease sales reached $927M, up 13.0%, helped by Livdelzi and pricing in hepatitis B and hepatitis C. Livdelzi's $203M quarter and 93.0% year-over-year growth stand out, particularly because the product is already the U.S. market leader in second-line primary biliary cholangitis.
Oncology is mixed but improving. Trodelvy produced $506M in third-quarter sales and reached an annual run rate of approximately $2.0B. Cell therapy sales were $355M, down 18.0% year over year because of competitive pressure. The contrast is important: Gilead has a growing antibody-drug conjugate business, but its CAR T franchise remains under pressure.
Veklury is now a small and declining contributor. Third-quarter sales fell 69.0% to $86M as COVID-19 hospitalizations decreased. The decline reduces the company's exposure to pandemic-related volatility, but it also removes a revenue source that was much larger in 2021 through 2023.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Biktarvy is Gilead's flagship product and the main reason the company generates such strong cash flow. Third-quarter sales of $4.1B rose 10.0% year over year, and U.S. treatment market share reached a record 53.0%. Management cited demand, realized pricing, and favorable inventory dynamics as the main drivers.
Biktarvy's advantages are practical as well as scientific. It is a single-tablet regimen, has strong physician familiarity, retains existing patients, and continues to gain share among new patients and treatment switches. Gilead also has a broad follow-on portfolio built around bictegravir and lenacapavir, giving the company more ways to retain patients as treatment preferences change.
The principal risk is policy-driven pricing. Biktarvy was selected for the Maximum Fair Price process, and management said the resulting price will affect Biktarvy revenue in 2028. That risk does not undermine current demand, but it puts a ceiling on how much of the franchise's growth can flow through to revenue and earnings.
Yeztugo is the most important newer product. It uses lenacapavir to provide twice-yearly HIV prevention, and more than 70.0% of users have returned for a second injection. Yeztugo and Descovy together hold 50.0% of the PrEP market and have a $4.0B annual run rate. That combination gives Gilead a meaningful position in prevention, not just treatment.
Gilead's strongest competitive advantage is its depth in HIV. Biktarvy supplies scale today, while Yeztugo and several lenacapavir programs extend the franchise into twice-yearly, once-weekly, and other long-acting formats. The company is advancing six long-acting HIV treatment programs and a once-weekly oral prevention application.
The pipeline also has meaningful oncology optionality. Gilead has seven clinical-stage antibody-drug conjugate programs, acquired four clinical-stage programs and next-generation ADC technology through Tubulis, and is evaluating Trodelvy in earlier-line breast cancer and endometrial cancer. These assets give the company more shots on goal than Trodelvy alone.
Inflammation is the longer-dated growth platform. Emvistegrast produced promising 12-week inflammatory bowel disease data and is scheduled to enter Phase 3 ulcerative colitis studies in 2027. Gilead also has an oral IL-23 receptor inhibitor program, an IRAK4 inhibitor, and gamgertamig, a BCMAxCD3 bispecific T-cell engager.
Management is investing in scale as well as molecules. Gilead announced a $32B U.S. research and manufacturing investment through 2030 and broke ground on a new biologics facility in 2026. That spending supports future biologics production, although it also raises the execution standard for the pipeline.
Gilead sells products through direct commercial teams, wholesalers, distributors, and corporate partners. It has marketing subsidiaries in more than 35 countries. In the United States, approximately 90.0% of historical gross product sales have flowed through Cardinal Health (CAH), Cencora (COR), and McKesson (MCK) and their specialty distribution affiliates.
That distribution structure provides reach but creates customer concentration among large wholesalers. The model also depends on payer coverage, specialty pharmacy access, and the ability of field teams to support physicians, hospitals, clinics, and other providers.
Gilead outsources much of its clinical trial work to contract research organizations. Those partners handle activities such as site identification, patient enrollment, monitoring, and bioanalysis. This structure limits the need for a fully internal trial network, but it makes vendor oversight and trial execution important operational controls.
Manufacturing capacity is becoming more strategic as the product mix shifts toward biologics, ADCs, and cell therapies. Anito-cel's targeted manufacturing turnaround of less than three weeks is a commercial advantage if Gilead can execute consistently after approval.
Gilead operates in markets where scientific differentiation and reimbursement access matter more than simple unit growth. The HIV market is supported by chronic treatment demand and prevention needs, while oncology is driven by new mechanisms, combination therapies, and earlier-line use.
The HIV market is moving toward long-acting dosing. Yeztugo's twice-yearly prevention schedule and the company's once-weekly oral programs address adherence and convenience, two commercial variables that can influence both new starts and switching. Gilead's prevention sales nearly doubled year over year in the third quarter, compared with 14.0% growth for the overall U.S. PrEP market.
Oncology is a larger but more contested market. Trodelvy's first-line metastatic triple-negative breast cancer approvals expand its addressable population, while the company's ADC pipeline targets ovarian, endometrial, and other solid tumors. The opportunity is substantial, but Merck (MRK), Bristol Myers Squibb (BMY), AstraZeneca (AZN), Roche (RHHBY), Novartis (NVS), and other large drugmakers have greater oncology scale.
The broader biotechnology industry is also adopting ADCs, cell therapies, bispecifics, precision medicine, and AI-assisted drug discovery. Gilead's $32B U.S. investment and its acquisitions in ADCs, T-cell engagers, and inflammation place the company inside those trends rather than outside them.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Gilead's customers include physicians, hospitals, clinics, specialty pharmacies, government programs, private insurers, wholesalers, and patients. The customer relationship differs by product. HIV therapies depend heavily on prescriber trust, long-term adherence, and coverage continuity, while oncology products require specialist adoption, treatment-center capability, and payer approval.
Biktarvy benefits from a large installed base and strong retention. Its 53.0% U.S. treatment share reflects physician and patient acceptance, while the product's single-tablet format simplifies daily treatment. Yeztugo serves a different need by reducing dosing frequency, and its 70.0% plus return rate for second injections provides an early measure of patient persistence.
Trodelvy and cell therapies have more specialized customer requirements. Treatment centers must manage infusion, monitoring, and reimbursement processes, while CAR T products require trained staff and manufacturing coordination. Gilead's target of activating 80.0% of authorized treatment centers within six months for anito-cel illustrates the operational work behind the commercial opportunity.
Payers are increasingly influential. Gilead's 10-K identifies private insurer and government pricing pressure as a major risk, and Biktarvy's Maximum Fair Price outcome gives that risk a specific 2028 financial consequence.
In HIV, ViiV Healthcare, part of GSK (GSK), is the most direct competitor. Merck (MRK), Johnson & Johnson (JNJ), and other pharmaceutical companies also compete across parts of HIV treatment and prevention. Gilead's advantage is the combination of Biktarvy's scale, its strong U.S. market share, and the breadth of its lenacapavir pipeline.
In oncology, Gilead faces a deeper field. Trodelvy competes with established breast cancer regimens, antibody-drug conjugates, immunotherapies, and combination approaches from Merck (MRK), Bristol Myers Squibb (BMY), AstraZeneca (AZN), Roche (RHHBY), Pfizer (PFE), and others.
Kite's cell therapy business competes with Novartis (NVS), Bristol Myers Squibb (BMY), AbbVie (ABBV), Roche (RHHBY), and emerging cell therapy developers. Third-quarter cell therapy sales falling 18.0% year over year confirms that Gilead's leadership in HIV does not automatically transfer to every therapeutic area.
The competitive conclusion is straightforward: Gilead owns a leading position in HIV, has a credible position in ADCs, and is still proving its durability in cell therapy and inflammation. That mix supports diversification, but it does not justify treating every pipeline asset as a commercial success before clinical and regulatory milestones are complete.
The most important policy issue for Gilead is U.S. drug pricing. CMS has completed the Maximum Fair Price process for Biktarvy, and management expects an effect on revenue in 2028. This creates a defined policy headwind for the company's largest product, even as current demand remains strong.
International access is another strategic factor. Gilead has partnered with the Pan American Health Organization to expand access to lenacapavir for HIV prevention across Latin America, and voluntary licenses cover 120 resource-limited countries, with generic rollout expected to begin in 2027. That approach can broaden public-health reach while creating a different commercial model from U.S. pricing.
Geopolitical and industrial policy also affect manufacturing. Gilead's planned $32B U.S. research and manufacturing investment through 2030 aligns its supply-chain expansion with domestic production priorities. The investment strengthens resilience, but it commits capital before the full commercial return from the pipeline is established.
The external backdrop therefore has two opposing forces. Government pricing programs pressure mature products, while public-health demand, advanced therapies, and domestic biomanufacturing investment support long-term industry growth.
Gilead ended the period with a B- balance sheet grade, reflecting solid cash generation but enough leverage and acquisition-related complexity to keep financial flexibility from looking pristine.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Third-quarter base business sales rose 16.0% year over year to $8.2B, with HIV revenue up 18.0% to $6.2B and Biktarvy alone contributing $4.1B.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised full-year 2026 base business revenue guidance by $1.6B, and Yeztugo is already tracking toward roughly $1.0B in full-year sales.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $170.68, GILD trades at 17.3x forward earnings with a 2.5x PEG and a 5.0% free-cash-flow yield, leaving the shares close to fair value.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The analyst target of $170.88 sits almost exactly on the current quote, reinforcing the report's Hold stance despite strong operating momentum.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Gilead Sciences has rebuilt its growth profile around a durable HIV franchise and a more credible group of products beyond HIV. Biktarvy remains the anchor, Yeztugo is creating a new prevention category, Trodelvy is scaling in breast cancer, and Livdelzi is gaining share in primary biliary cholangitis.
The company also generates enough cash to fund research, acquisitions, manufacturing, dividends, and buybacks. That financial engine is the reason the balance sheet can carry meaningful debt without becoming the central investment problem.
The stock's challenge is price discipline. GILD is near the analyst consensus target, carries a 2.5x PEG ratio, and faces a defined 2028 Biktarvy pricing headwind. A Hold is therefore the most balanced stance at $170.68. A materially lower entry price would improve the risk-reward, while a materially higher price would require stronger evidence that the pipeline can replace policy-sensitive HIV growth.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Gilead Sciences, Inc. (GILD) gains after a stronger-than-expected earnings report, but the real story is deeper than the headline beat. This analysis breaks down revenue momentum, HIV and Yeztugo growth, acquisition-related charges, and what the latest guidance means for the stock.
Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Gilead Sciences, Inc. (GILD) gains 2.6% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.